Digital health is unlocking new avenues for innovation across life sciences, and industry leaders are keen to tap into the potential of this burgeoning area.
Digital health is unlocking new avenues for innovation across life sciences, and industry leaders are keen to tap into the potential of this burgeoning area.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh